Pierre Freres
@pierrefreres.bsky.social
Oncomed, brain tumors, lung cancer, AYA patients.
Reposted by Pierre Freres
Surveillance with [18F]FDG PET/CT of stage I-III lung cancer patients after completion of curative treatment
www.jto.org/article/S155...
suggest routine use of PET/CT for surveillance in #NSCLC does not offer a clinical advantage over standard CT, questioning its value in routine FU care
www.jto.org/article/S155...
suggest routine use of PET/CT for surveillance in #NSCLC does not offer a clinical advantage over standard CT, questioning its value in routine FU care
April 29, 2025 at 8:27 AM
Surveillance with [18F]FDG PET/CT of stage I-III lung cancer patients after completion of curative treatment
www.jto.org/article/S155...
suggest routine use of PET/CT for surveillance in #NSCLC does not offer a clinical advantage over standard CT, questioning its value in routine FU care
www.jto.org/article/S155...
suggest routine use of PET/CT for surveillance in #NSCLC does not offer a clinical advantage over standard CT, questioning its value in routine FU care
Reposted by Pierre Freres
#Medsky #OncSky
Did you know that for sedentary people 1-2 min bursts of activity (VILPA, vigorous intermittent lifestyle physical activity) like running for the bus or racing up a couple flights of stairs for a forgotten item is assoc w/ reduced risk of cancer & mortality? go.nature.com/4fVAh5P
Did you know that for sedentary people 1-2 min bursts of activity (VILPA, vigorous intermittent lifestyle physical activity) like running for the bus or racing up a couple flights of stairs for a forgotten item is assoc w/ reduced risk of cancer & mortality? go.nature.com/4fVAh5P
Even a small dose of physical activity can be good medicine
Nature Medicine - Studies from wearables show that even small doses of physical activity provide health benefits; guidelines should be updated to reflect this.
go.nature.com
January 15, 2025 at 3:53 AM
#Medsky #OncSky
Did you know that for sedentary people 1-2 min bursts of activity (VILPA, vigorous intermittent lifestyle physical activity) like running for the bus or racing up a couple flights of stairs for a forgotten item is assoc w/ reduced risk of cancer & mortality? go.nature.com/4fVAh5P
Did you know that for sedentary people 1-2 min bursts of activity (VILPA, vigorous intermittent lifestyle physical activity) like running for the bus or racing up a couple flights of stairs for a forgotten item is assoc w/ reduced risk of cancer & mortality? go.nature.com/4fVAh5P
Reposted by Pierre Freres
One of the forgotten costs of cancer therapy is time spent in the clinic. Report on time toxicity in JCO Oncology Practice on pts with lung cancer showed 22% of days alive had in person visits: 24% with chemotherapy, 21% for immunotherapy, 16% for targeted therapy. #LCSM
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Time Toxicity of Systemic Anticancer Therapy for Metastatic Lung Cancer in Routine Clinical Practice: A Nationwide Cohort Study | JCO Oncology Practice
PURPOSEThe concept of time toxicity of cancer treatment, defined as proportion of days from
physical contact with the health care system, has been suggested as simple, patient-centered
measure useful ...
ascopubs.org
December 23, 2024 at 9:44 AM
One of the forgotten costs of cancer therapy is time spent in the clinic. Report on time toxicity in JCO Oncology Practice on pts with lung cancer showed 22% of days alive had in person visits: 24% with chemotherapy, 21% for immunotherapy, 16% for targeted therapy. #LCSM
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Reposted by Pierre Freres
#MedSky #IDSky
“A 2020 paper that sparked widespread enthusiasm for hydroxychloroquine as a #COVID19 treatment was retracted today…because of ethical concerns & methodological problems, according to a retraction notice.”
www.science.org/content/arti...
“A 2020 paper that sparked widespread enthusiasm for hydroxychloroquine as a #COVID19 treatment was retracted today…because of ethical concerns & methodological problems, according to a retraction notice.”
www.science.org/content/arti...
Infamous paper that popularized unproven COVID-19 treatment finally retracted
Study on hydroxychloroquine by Didier Raoult and colleagues gets pulled on ethical and scientific grounds
www.science.org
December 17, 2024 at 9:31 PM
#MedSky #IDSky
“A 2020 paper that sparked widespread enthusiasm for hydroxychloroquine as a #COVID19 treatment was retracted today…because of ethical concerns & methodological problems, according to a retraction notice.”
www.science.org/content/arti...
“A 2020 paper that sparked widespread enthusiasm for hydroxychloroquine as a #COVID19 treatment was retracted today…because of ethical concerns & methodological problems, according to a retraction notice.”
www.science.org/content/arti...
Reposted by Pierre Freres
Can gender & genetics impact alectinib tox? @jtoonline.bsky.social
- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox
#Medsky #Oncsky #LCSM
www.jto.org/article/S155...
- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox
#Medsky #Oncsky #LCSM
www.jto.org/article/S155...
Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer
Alectinib, a small-molecule kinase inhibitor, is used as first-line treatment for anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC). Albeit generally well-tolerated, a considerable subset of patients requires dose adjustments due to drug-related toxicity. Single-nucleotide polymorphisms (SNPs) in genes related to the metabolism of alectinib may upfront identify patients at risk for toxicity.
www.jto.org
December 9, 2024 at 8:46 PM
Can gender & genetics impact alectinib tox? @jtoonline.bsky.social
- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox
#Medsky #Oncsky #LCSM
www.jto.org/article/S155...
- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox
#Medsky #Oncsky #LCSM
www.jto.org/article/S155...
Reposted by Pierre Freres
We have known for decade+ that you can detect progression using ctDNA months before you see it on scans. But until we show that it impacts outcomes to change tx earlier all it does is make ppl anxious and abandon treatments (TKIs) that may still be helping. Most MRD use today is marketing over data.
Why aren’t more oncologists using MRD tests like Signatera or Guardant Reveal to proactively treat NSCLC before PD shows up on imaging especially in later treatment lines? www.jto.org/article/S155...
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3
EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitizing and -resistance mutations may be detected in plasma through circulating tumor DNA (ctDNA). Circulating tumor DNA level changes reflect alterations in tumor burden and could be a dynamic indicator of treatment effect. This analysis aimed to determine whether longitudinal EGFR-mutation ctDNA testing could detect progressive disease (PD) before radiologic detection.
www.jto.org
December 8, 2024 at 1:06 PM
We have known for decade+ that you can detect progression using ctDNA months before you see it on scans. But until we show that it impacts outcomes to change tx earlier all it does is make ppl anxious and abandon treatments (TKIs) that may still be helping. Most MRD use today is marketing over data.
Reposted by Pierre Freres
A modeling study led by the NIH, published in JAMA Oncology, found that advances in cancer prevention and screening have averted more deaths from breast, cervical, colorectal, lung, and prostate cancers over the past 45 years than treatment advancements.
A modeling study led by the NIH, published in *JAMA Oncology*, found that advances in cancer prevention and screening have averted more deaths from breast, cervical, colorectal, lung, and prostate cancers over the past 45 years than treatment advancements.
Impacts of prevention, screening, treatment on cancer deaths
An NCI modeling study finds that, over the past 45 years, the majority of deaths averted from five cancer types were due to prevention and screening.
buff.ly
December 6, 2024 at 4:14 PM
A modeling study led by the NIH, published in JAMA Oncology, found that advances in cancer prevention and screening have averted more deaths from breast, cervical, colorectal, lung, and prostate cancers over the past 45 years than treatment advancements.
Reposted by Pierre Freres
Reposted by Pierre Freres
We are excited to be Shining the Spotlight on the work of Rising 🌟, Dr. Ivy Riano of Dartmouth as she discusses Broadened Eligibility Criteria in Lung Cancer Clinical Trials for Patients w Brain Metastasis on MedNews Week Medical Spotlight in partnership w OncLive.
www.onclive.com/view/adoptin...
www.onclive.com/view/adoptin...
Adopting Broader Clinical Trial Eligibility in Lung Cancer With Brain Mets, Leptomeningeal Disease
Ivy Riano, MD, of Dartmouth Geisel School of Medicine, discusses the adoption of broader clinical trial eligibility in lung cancer, specifically for those with brain metastases or leptomeningeal disea...
www.onclive.com
November 12, 2024 at 1:35 AM
We are excited to be Shining the Spotlight on the work of Rising 🌟, Dr. Ivy Riano of Dartmouth as she discusses Broadened Eligibility Criteria in Lung Cancer Clinical Trials for Patients w Brain Metastasis on MedNews Week Medical Spotlight in partnership w OncLive.
www.onclive.com/view/adoptin...
www.onclive.com/view/adoptin...
Reposted by Pierre Freres
Pleased to share our paper on the impact of severe irAEs in adv NSCLC #TheOncologist
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE
@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE
@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...
Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors
AbstractBackground. Immune checkpoint inhibitors (ICIs) are associated with severe immune-related adverse events (s-irAEs) that result in hospitalization,
academic.oup.com
December 1, 2024 at 12:36 AM
Pleased to share our paper on the impact of severe irAEs in adv NSCLC #TheOncologist
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE
@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE
@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...
Reposted by Pierre Freres
I believe this is at least in part because of internalized stigma. People with a history of cigarette use may feel like like if they do have lung cancer, they deserve it, and won't be supported. There need to be clear messaging that all lung cancer patients deserve the best care #lcsm #oncsky
Around 75% of current or former smokers had not discussed the option of lung cancer screening via low dose CT with a clinician, based on recent survey data. So many missed opportunities jamanetwork.com/journals/jam...
Lung Cancer Screening Communication in the US, 2022
This cross-sectional study examines lung cancer screening communication between US clinicians and patients by smoking status and demographic, socioeconomic, and clinical characteristics.
jamanetwork.com
November 19, 2024 at 1:45 AM